Sustained-Release Performance In Vitro of BCG/Fe₃O₄/Chitosan Thermosensitive Gel Integrated Material for Irrigation Therapy of the Bladder Tumor

Abstract:

Tumor of bladder is one of the most common tumors of the urinary system, the vast majority of which come from the epithelial tissue, and of which more than 90% are transitional cell tumors. Tumor of bladder ranks fourth in men and tenth in women. Intravesical instillation of Bacillus Calmette-Guerin (BCG) is recognized as the best way to prevent the recurrence of bladder cancer. But BCG would be excreted with the urine after staying about one hour in the bladder, which has a serious impact on its efficacy. In addition, repeated infusions bring great pains to the patients. This research intends to design a new sustained-release BCG integrated composite materials based on homogenized freeze-dried BCG. The release experiments in vitro of the composite materials show that the release property is good and release time of BCG is more than 48 hours.

• Periodical: Key Engineering Materials (Volumes 609-610)
• Pages: 867-874
• DOI: https://doi.org/10.4028/www.scientific.net/KEM.609-610.867
• Online since: April 2014
• Authors: Cheng Ge Wu*, Kang Ning Sun, Ai Min Li
• Keywords: BCG, Bladder Tumor, CS, Fe₃O₄, Sustained-Release

References

[1] Razack, A.H.A.: Bacillus Calmette–Guérin and Bladder Cancer. Asian Journal of Surgery, 30(4) (2007), pp.302-309.

DOI: 10.1016/s1015-9584(08)60045-7

[2] Rosevear, H.M., et al.: Safety and Efficacy of Intravesical Bacillus Calmette-Guérin Plus Interferon α-2b Therapy for Nonmuscle Invasive Bladder Cancer in Patients With Prosthetic Devices. The Journal of Urology, 184(5) (2010), p.1920-(1924).

DOI: 10.1016/j.juro.2010.06.149

[3] Swietek, N., et al.: The Value of Transurethral Bladder Biopsy after Intravesical Bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer: A Retrospective, Single Center Study and Cumulative Analysis of the Literature. The Journal of Urology, 188(3) (2012).

DOI: 10.1016/j.juro.2012.05.015

[4] Pan, C. -W., Z. -J. Shen, and G. -Q. Ding: The Effect of Intravesical Instillation of Antifibrinolytic Agents on Bacillus Calmette-Guerin Treatment of Superficial Bladder Cancer: A Pilot Study. The Journal of Urology, 179(4) (2008), pp.1307-1312.

DOI: 10.1016/j.juro.2007.11.045

[5] Solsona, E., et al.: Feasibility of Radical Transurethral Resection as Monotherapy for Selected Patients With Muscle Invasive Bladder Cancer. The Journal of Urology, 184(2) (2010), pp.475-481.

DOI: 10.1016/j.juro.2010.04.008

[6] Phull, J.S., et al.: Modern transurethral resection in the management of superficial bladder tumours. British Journal of Medical and Surgical Urology, 4(3) (2011), pp.91-100.

DOI: 10.1016/j.bjmsu.2010.11.004

[7] Herr, H.W. and A. Morales: History of Bacillus Calmette-Guerin and Bladder Cancer: An Immunotherapy Success Story. The Journal of Urology, 179(1) (2008), pp.53-56.

DOI: 10.1016/j.juro.2007.08.122

[8] Ahn, J.J. and J.M. McKiernan: New Agents for Bacillus Calmette-Guérin–Refractory Bladder Cancer. Urologic Clinics of North America, 40(2) (2013), pp.219-232.

DOI: 10.1016/j.ucl.2013.01.008

[9] Freichels, H., R. Jérôme, and C. Jérôme: Sugar-labeled and PEGylated (bio)degradable polymers intended for targeted drug delivery systems. Carbohydrate Polymers, 86(3) (2011), pp.1093-1106.

DOI: 10.1016/j.carbpol.2011.06.004

[10] Kumar, A., X. Zhang, and X. -J. Liang: Gold nanoparticles: Emerging paradigm for targeted drug delivery system. Biotechnology Advances, (0).

DOI: 10.1016/j.biotechadv.2012.10.002

[11] Muro, S.: Challenges in design and characterization of ligand-targeted drug delivery systems. Journal of Controlled Release, 164(2) (2012), pp.125-137.

DOI: 10.1016/j.jconrel.2012.05.052

[12] Park, J.H., et al.: Targeted delivery of low molecular drugs using chitosan and its derivatives. Advanced Drug Delivery Reviews, 62(1) (2010), pp.28-41.

DOI: 10.1016/j.addr.2009.10.003

[13] Kim, J. -H., et al.: Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. Journal of Controlled Release, 127(1) (2008), pp.41-49.

DOI: 10.1016/j.jconrel.2007.12.014

[14] Wang, C., et al.: Synthesis of the KMB-Drug Delivery Carrier. Physics Procedia, 33(0) (2012), pp.20-24.

[15] Yu, J., et al.: Poly(ethylene glycol) shell-sheddable magnetic nanomicelle as the carrier of doxorubicin with enhanced cellular uptake. Colloids and Surfaces B: Biointerfaces, 107(0) (2013), pp.213-219.

DOI: 10.1016/j.colsurfb.2013.02.009

[16] Chenite, A., et al.: Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Biomaterials, 21(21) (2000), pp.2155-2161.

DOI: 10.1016/s0142-9612(00)00116-2